Home » Market News » DirectorsTalk Highlights » How are EpiSwitch markers detected?
Oxford BioDynamics

How are EpiSwitch markers detected?

Introduction: Getting the basics right

Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease biology in individual patients. The company has developed an International Organization for Standardization (ISO) compliant clinical grade testing platform for quantitative real-time Polymerase Chain Reaction (qPCR) experiments and is actively working with their pharmaceutical and biotechnology industry partners to enable their precision medicine

Approved genomic tests and the Federal Drug Administration (FDA)

PCR-based techniques are considered by the FDA as one of the ‘gold-standard’ technologies used for the validation of experimental results, and numerous PCR-based diagnostic assays have been approved in the last decade. In fact, approximately 40% of nucleic acid-based tests and companion diagnostics approved by the FDA through 2017 utilized PCRbased detection methodologies.

Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer, ALS and other diseases.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.